ArticleDigestive diseases and sciences2010
Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?
Article in Digestive diseases and sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Trial
- Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.World journal of gastroenterology · 2022Trial
- Clinical characteristics and risk factors of refractory gastroesophageal reflux disease: A multicenter cross-sectional study.World journal of gastroenterology · 2025Observational
- Awareness, attitudes, and clinical utilization of vonoprazan for Helicobacter pylori infection and gastroesophageal reflux disease among Chinese physicians: a nationwide cross-sectional study.BMC gastroenterology · 2025Article
- Knowledge, Attitudes, and Practices of Community Pharmacists Regarding Proton Pump Inhibitor (PPI) Use: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment.BMC gastroenterology · 2025Article
- A safety and effectiveness evaluation of refluxstop in the treatment of acid reflux comparing large and small hiatal hernia groups: results from 99 patients in Switzerland with up to 4-years follow-up.Hernia : the journal of hernias and abdominal wall surgery · 2025Article
- RETRACTED: A Phase III Head-to-Head Study to Compare the Efficacy and Safety of Fexuprazan and Esomeprazole in Treating Patients with Erosive Esophagitis.Journal of clinical medicine · 2024Article
- GERD: Latest update on acid-suppressant drugs.Current research in pharmacology and drug discovery · 2024Article
- A scientometrics analysis and visualization of refractory gastroesophageal reflux disease.Frontiers in pharmacology · 2024Article
- Long-term potassium-competitive acid blockers administration causes microbiota changes in rats.Surgical endoscopy · 2023Article
- Review
- [Treatment of Acid-related Diseases Using Potassium-competitive Acid Blockers].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2022Review
- Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers.Clinical and translational science · 2021Article
- Review
- Community-dwelling older adults' awareness of the inappropriate use of proton pump inhibitors.BMC geriatrics · 2020Article
- Article
- Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases.Journal of neurogastroenterology and motility · 2018Review
- Patient Values and Preferences Surrounding Proton Pump Inhibitor Use: A Scoping Review.The patient · 2018Article
- Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.Digestive diseases and sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD).
aimThe aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD.
methodsSeparate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects.
resultsMost respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as "somewhat satisfied" to "completely dissatisfied" with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004).
conclusionsApproximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.
Indexed as
Identifiers
20397047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.